T cell receptor alpha variable 5Genealiases: TCRAV15S1 · TCRAV5S1
Q-omics provides the consensus-scored TRAV5 profile across patient tissues and cancer cell-line models. TRAV5 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, TRAV5 is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, TRAV5 RNA expression shows 14,412 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight HNSC, KIRC, and DLBC as cancer lineages where TRAV5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRAV5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRAV5 survival associations across molecular data types. TRAV5 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRAV5 RNA expression–survival associations across cancer types. High TRAV5 expression shows unfavorable associations in UVM, but favorable associations in HNSC, SKCM, BLCA, BRCA and SARC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for TRAV5 RNA expression.
This table summarizes TRAV5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TRAV5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRAV5 shows lower tumor expression in THCA, COAD, KICH and LUSC and higher tumor expression in KIRC and STAD. The KIRC box plot shows higher TRAV5 RNA expression in tumor versus normal tissue (log2 FC = +1.119, t-test p < 0.001).
This table shows molecular features associated with TRAV5 in patient tissues and cancer cell lines. In patient samples, TRAV5 shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set.
